Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Active, not recruiting
National Cancer Institute (NCI)
Phase 2
2014-03-25
This phase II trial studies how well combination chemotherapy before and after surgery works
in treating patients with localized pancreatic cancer. Drugs used in chemotherapy, such as
leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving combination chemotherapy before surgery may make the tumor smaller
and reduce the amount of normal tissue that needs to be removed. Giving these treatments
after surgery may kill any tumor cells that remain after surgery.
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Active, not recruiting
Yale University
Phase 2
2014-03-25
This phase II trial studies how well combination chemotherapy before and after surgery works
in treating patients with localized pancreatic cancer. Drugs used in chemotherapy, such as
leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving combination chemotherapy before surgery may make the tumor smaller
and reduce the amount of normal tissue that needs to be removed. Giving these treatments
after surgery may kill any tumor cells that remain after surgery.
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
Recruiting
New York State Institute for Basic Research
Phase 2
2020-09-22
The primary objective of this study is to evaluate the cognitive and behavioral effects of
liquid leucovorin calcium on young children with autism spectrum disorder (ASD) and determine
whether it improves language as well as the core and associated symptoms of ASD. The
investigators will enroll 80 children across two sites, between the ages of 2.5 and 5 years,
with confirmed ASD and known language delays or impairments. Participation will last
approximately 26 weeks from screening to end of treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
